McDonald's(US:MCD) Jing Ji Guan Cha Wang·2026-02-13 16:40Core Viewpoint - McDonald's reported better-than-expected performance in its Q4 and full-year 2025 financial results, indicating strong operational resilience and growth potential in various markets [1]. Financial Performance - Q4 Revenue: $7.009 billion, a 6% increase year-over-year (fixed exchange rate), surpassing market expectations [2]. - Net Profit: $2.164 billion, a 4% year-over-year increase [3]. - Adjusted Earnings Per Share: $3.12, exceeding analyst expectations of $3.04 [4]. - Global Same-Store Sales: Increased by 5.7%, significantly above the market expectation of 3.7% [5]. Regional Performance - U.S. Market: Same-store sales grew by 6.8%, marking the third consecutive quarter of growth, driven by value meal strategies attracting price-sensitive consumers [6]. - International Markets (e.g., UK, Germany, Australia): Same-store sales increased by 5.2%, with nearly all markets showing growth [7]. - International Development Markets (e.g., Japan, China): Same-store sales grew by 4.5%, with China maintaining stable market share despite macroeconomic pressures and plans to open over 1,000 new restaurants in 2025 [7]. Annual Performance - Full-Year Revenue: $26.885 billion, a 2% year-over-year increase [8]. - Full-Year Net Profit: $8.563 billion, a 3% year-over-year increase [9]. - Cash Flow: Operating cash flow reached $10.55 billion, highlighting financial resilience [10]. Strategic Initiatives - Store Expansion: In 2025, 2,275 new restaurants were opened, with plans for approximately 2,600 new openings in 2026 (net increase of 2,100), including about 1,000 in China, aiming for a total of 50,000 global locations by 2027 [11]. - Product Innovation: New products such as energy drinks and specialty iced coffee will be launched in 2026, alongside a focus on promoting high-protein offerings to align with health trends [12]. - Capital Expenditure: Expected investment of $3.7 to $3.9 billion in 2026, primarily for new store openings [13]. Company Outlook - CEO Chris Kempczinski noted that the value strategy effectively increased customer traffic, with no significant impact observed from GLP-1 weight loss drugs on business [14]. - The company anticipates maintaining an operating profit margin above 40% in the mid-to-high range for 2026 [15].